Latest News

It's not a stretch to say that SH Energy & Chemical Co., Ltd.'s ( KRX:002360 ) price-to-sales (or "P/S") ratio of 0.4x...

When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") below 15x, you may consider...

Bioxyne Limited ( ASX:BXN ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...

The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more...

ReadyTech Holdings Limited ( ASX:RDY ) shares have had a horrible month, losing 26% after a relatively good period...

Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying...

Unfortunately for some shareholders, the Life360, Inc. ( ASX:360 ) share price has dived 27% in the last thirty days...

EssilorLuxottica Société anonyme (ENXTPA:EL) has put fresh numbers on the table for FY 2025, with second half revenue of €14.5b, basic EPS of €2.01 and net income of €928m, while trailing twelve month revenue sits at €28.5b with EPS of €5.04 and net income of €2.3b. The company has seen revenue move from €13.2b and EPS of €2.18 in 2024 H2 to €14.5b and EPS of €2.01 in 2025 H2, alongside forecast annual revenue growth of 8.1% and EPS growth of 13.3%. Investors are likely to focus on how these...

The Star Entertainment Group Limited ( ASX:SGR ) shares have retraced a considerable 26% in the last month, reversing a...

When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") above 22x, you may consider...

WAM Strategic Value Limited ( ASX:WAR ) will pay a dividend of A$0.0325 on the 29th of May. The dividend yield will be...

TELUS (TSX:T) has put fresh numbers on the table for FY 2025, with third quarter revenue at CA$5.1b and basic EPS of CA$0.32 alongside net income of CA$493m as investors weigh the latest move in margins. The company has seen quarterly revenue move between CA$4.9b and CA$5.3b over the past six reported periods, while basic EPS has ranged from roughly CA$0.00 to CA$0.32. This sets a clear backdrop for how current earnings fit within its recent history. With net profit margins now sitting above...

Anheuser-Busch InBev (ENXTBR:ABI) has wrapped up FY 2025 with fourth quarter revenue of about US$15.6b and basic EPS of US$0.99, rounding out a year where trailing 12 month revenue reached roughly US$59.3b and EPS came in at US$3.45. Over the past few quarters, revenue has moved from US$14.8b in Q4 2024 to US$15.0b in Q2 2025 and US$15.1b in Q3 2025, while quarterly EPS has ranged between US$0.53 and US$1.08, setting up a picture of higher trailing profitability alongside a net profit margin...

Sterling Infrastructure, Inc. ( NASDAQ:STRL ) shareholders have had their patience rewarded with a 34% share price jump...

Verisure (OM:VSURE) FY 2025 Earnings Snapshot Verisure (OM:VSURE) has wrapped up FY 2025 with fourth quarter revenue of €964.7 million and a basic EPS loss of €0.12, while trailing 12 month figures show revenue of about €3.7 billion and a basic EPS loss of €0.30. Over the past year, the company has seen revenue move from €870.2 million in Q4 2024 to €964.7 million in Q4 2025, while quarterly EPS stayed in loss making territory, shifting from a €0.07 loss per share in Q4 2024 to a €0.12 loss...

Mibanco, the microfinance arm of Credicorp (NYSE:BAP), is partnering with Temenos to modernize its core banking platform using software as a service. The collaboration focuses on faster product launches, improved customer experience, and broader financial inclusion for small businesses in Peru. For Credicorp, which has a strong presence in microfinance through Mibanco, this tech upgrade relates directly to how banking services are delivered to small and midsize enterprises in Peru. The move...

Civmec (ASX:CVL) has laid out a fresh set of H1 2026 numbers, with the latest half showing total revenue of A$307.7 million and basic EPS of A$0.03 alongside net income of A$16.0 million. Over recent halves the company has seen revenue move from A$541.1 million and EPS of A$0.06 in H2 2024 to A$502.9 million and EPS of A$0.05 in H1 2025. This sets the backdrop for today’s update and the current share price of A$1.56, and investors are now weighing those headline figures against slightly...

Confluent (CFLT) just wrapped up FY 2025 with Q4 revenue of US$314.8 million and a basic EPS loss of US$0.23, while trailing twelve month revenue sat at about US$1.17 billion against a full year basic EPS loss of US$0.86. Over recent quarters, the company has seen revenue move from US$261.2 million in Q4 2024 to US$314.8 million in Q4 2025, with quarterly basic EPS losses ranging between US$0.19 and US$0.27. The latest print keeps the spotlight firmly on how quickly revenue growth can offset...

LINK Mobility Group Holding (OB:LINK) has just posted its FY 2025 numbers, with fourth quarter revenue of NOK1.98b and basic EPS of NOK0.10 setting the tone for a year where trailing 12 month revenue came in at NOK7.08b and EPS at NOK0.28. Over recent quarters the company has seen revenue move between NOK1.65b and NOK1.98b, while quarterly EPS ranged from close to zero to NOK0.13, giving investors a mixed but readable picture of earnings power. With trailing net margins sitting in the low...

If you are wondering whether PennyMac Mortgage Investment Trust is offering good value at its recent share price, you are not alone. This article is designed to help you make sense of that question. The stock most recently closed at US$12.49, with returns of 2.0% over the past week, a 5.2% decline over the past month, a 1.3% decline year to date, and a 3.4% return over the last year, alongside cumulative returns of 26.2% over three years and 22.1% over five years. Recent coverage has focused...

Sarepta Therapeutics (NasdaqGS:SRPT) received Medsafe approval in New Zealand for its first-in-human clinical trial of SRP-1005. SRP-1005 is an investigational siRNA therapeutic targeting Huntington's Disease, a severe neurodegenerative condition. The authorization allows Sarepta to begin a Phase 1 study, marking its clinical entry into Huntington's Disease research. Sarepta Therapeutics is best known for its Duchenne muscular dystrophy franchise, and SRP-1005 broadens its rare disease...

Core Natural Resources (CNR) has posted a mixed set of FY 2025 numbers, with Q3 revenue at about US$1.0 billion and basic EPS of US$0.61 alongside a trailing twelve month loss of US$43.4 million on basic EPS of US$0.94. The company has seen quarterly revenue move from US$553.4 million in Q3 2024 to more than US$1.0 billion in Q3 2025, while basic EPS has swung between a profit of US$3.23 and a loss of US$1.38 over that stretch. This highlights how volatile margins have been. For investors,...

Mitsubishi Materials (TSE:5711) Q3 2026 earnings snapshot Mitsubishi Materials (TSE:5711) has reported Q3 2026 revenue of ¥454.6b and basic EPS of ¥236.47, backed by net income of ¥30.9b for the quarter. The company’s revenue moved from ¥494.1b in Q3 2025 to ¥454.6b in Q3 2026, while quarterly EPS shifted from ¥187.54 to ¥236.47 over the same period, against a trailing twelve month EPS of ¥162.93 on revenue of ¥1.76t. This combination of a softer top line and firmer per share earnings focuses...

Inpex (TSE:1605) has just wrapped up FY 2025 with fourth quarter revenue of ¥490,704 million and basic EPS of ¥86.17, while trailing twelve month figures sit at ¥2.0 trillion in revenue and EPS of ¥337.94, giving investors a clear view of both the latest quarter and the full year run rate. Over recent periods, revenue has moved from ¥518,280 million and EPS of ¥115.17 in Q4 2024 to ¥490,704 million and EPS of ¥86.17 in Q4 2025, with trailing net profit margin at 19.6% compared with 18.9% a...